Alaa Latif, MD
Hematology-Oncology · Pomona, CANPI 1619965506
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,558 of the $3,062 with a category attached, or 83.5%. It is spread thinly across 27 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,190 and has fallen 98.6% since, to $16 in 2025. That places this record below the midpoint for hematology-oncology clinicians in CA, where the typical reported total is $1,839.
Across 126 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$514
- Johnson & Johnson$351
- E.r. Squibb & Sons, L.L.C.$350
- Incyte Corporation$260
- Bristol Myers Squibb$241
- AstraZeneca$142
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,55884%
- Education$50416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 28 | $514 |
| Johnson & Johnson(2 entities) | 13 | $351 |
| E.r. Squibb & Sons, L.L.C. | 16 | $350 |
| Incyte Corporation | 5 | $260 |
| Bristol Myers Squibb | 11 | $241 |
| AstraZeneca(2 entities) | 6 | $142 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $120 |
| AVEO Pharmaceuticals, Inc. | 4 | $119 |
| Amgen | 4 | $118 |
| Sobi, Inc | 4 | $112 |
| Beigene USA, Inc. | 3 | $99 |
| Pfizer | 5 | $96 |
| Novartis | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| EMD Serono, Inc. | 2 | $58 |
| Sanofi | 2 | $49 |
| Deciphera Pharmaceuticals Inc. | 2 | $48 |
| ADC Therapeutics America, Inc. | 1 | $34 |
| Bayer | 1 | $32 |
| Seagen Inc. | 1 | $31 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Medtronic | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$3,062 in reported general payments places this provider in the 50th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 28 | $470,161 |
| QinlockRipretinib | 11 | $458,742 |
| Lenalidomide | 25 | $323,130 |
| SprycelDasatinib | 13 | $267,564 |
| TasignaNilotinib Hcl | 11 | $211,316 |
| ImbruvicaIbrutinib | 11 | $179,942 |
| DarzalexDaratumumab | 20 | $145,823 |
| XgevaDenosumab | 15 | $48,699 |
| DopteletAvatrombopag Maleate | 13 | $43,128 |
| EliquisApixaban | 40 | $27,303 |
| XareltoRivaroxaban | 25 | $26,696 |
| Bortezomib | 13 | $15,492 |
| Fosaprepitant Dimeglumine | 11 | $2,948 |
| Anastrozole | 133 | $2,005 |
| Imatinib Mesylate | 15 | $1,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $241 | $470,16128 claims |
| Deciphera Pharmaceuticals Inc.Qinlock | $48 | $458,74211 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $350 | $267,56413 claims |
| NovartisTasigna | $86 | $211,31611 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $120 | $179,94211 claims |
| Johnson & JohnsonDarzalex, Xarelto | $351 | $172,51845 claims |
| AmgenXgeva | $118 | $48,69915 claims |
| PfizerEliquis | $96 | $27,30340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in Pomona
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
- Brian ChoiRiverside$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.